Duloxetine Capsule, Delayed Release
Product Images NDC 70518-1011

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 70518-1011). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride, an active ingredient in the drug Duloxetine. The diagram shows the molecular arrangement including thiophene, naphthalene rings, and an amine group complexed with hydrochloride.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A Kaplan-Meier survival curve chart depicting the proportion of patients with relapse over time in days from randomization. The chart compares relapse rates between Duloxetine and placebo treatment groups, showing lower relapse proportion in patients treated with Duloxetine throughout the study period up to 200 days.*

FDA Label Image

Figure2 (Duloxetine Fig2)

A Kaplan-Meier curve chart showing the proportion of patients with relapse over time from randomization to relapse in days, comparing placebo and duloxetine treatment groups. The x-axis represents time in days (0 to 300), and the y-axis represents the proportion of patients with relapse (0.0 to 1.0). The chart illustrates a higher relapse proportion in the placebo group over time compared to the duloxetine group.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at different dosages (60 mg BID, 60 mg QD, 20 mg QD) and placebo. The graph plots pain improvement percentages on the x-axis and patient improvement percentages on the y-axis, comparing effectiveness across treatments.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo. The x-axis represents percent improvement from 0 to 100, and the y-axis represents percentage of patients improved up to 70%. Three lines compare the treatments' effectiveness, with Duloxetine groups showing higher patient improvement than placebo.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph comparing the percentage of patients improved against percent improvement in pain from baseline. It includes three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The y-axis shows the percentage of patients improved, and the x-axis shows percent improvement in pain, ranging from 0 to 100.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at 120 mg, 60 mg, 20 mg once daily doses and placebo. The graph illustrates patient response to different Duloxetine doses compared to placebo across increasing levels of pain improvement.*

FDA Label Image

Figure7 (Duloxetine Fig7)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline, showing data for Duloxetine 60 mg once daily and placebo. The x-axis represents percent improvement in pain, ranging from greater than 0 to 100, while the y-axis shows the percentage of patients improved, from 0 to 100%. Duloxetine demonstrates higher patient improvement percentages across the pain improvement spectrum compared to placebo.*

FDA Label Image

Figure8 (Duloxetine Fig8)

A line graph compares the percentage of patients improved with Duloxetine 60/120 mg once daily versus placebo. The x-axis shows percent improvement in pain from baseline, and the y-axis shows the percentage of patients improved. Duloxetine consistently shows higher improvement percentages across the range compared to placebo.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved by percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily versus placebo. The x-axis represents percent improvement in pain, ranging from >0 to 100, and the y-axis shows the percentage of patients improved, from 0 to 100%. Two data series are plotted: one for Duloxetine 60 mg once daily (solid line with diamond markers) and one for placebo (dashed line with 'x' markers), illustrating higher patient improvement percentages for Duloxetine across the pain improvement range.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved between placebo and Duloxetine 60/120 mg once daily treatments. The x-axis shows percent improvement in pain from baseline (BOCF) ranging from 0 to 100, and the y-axis shows the percentage of patients improved, also from 0 to 100. The Duloxetine line indicates consistently higher patient improvement percentages than placebo across the pain improvement spectrum.*

FDA Label Image

Mm1 (Duloxetine 60mg 70518 1011 00)

Duloxetine 60 mg delayed-release capsules, package quantity 30, labeled by RemedyRepack Inc. The label includes the NDC number 70518-1011-00, barcode, QR code, and manufacturer details listing Ajanta Pharma Ltd., Paithan, India. Storage instructions at 20-25°C (68-77°F) with permitted excursions 15-30°C (59-86°F) are provided. Directions refer to package insert.*

FDA Label Image

Mm2 (Duloxetine 60mg 70518 1011 01)

Label for Duloxetine 60 mg delayed-release capsules, quantity 30, from RemedyRepack Inc. The label includes a barcode, NDC number 70518-1011-01, and states the manufacturer as Ajanta Pharma Ltd., Paithan, India. It provides storage instructions and directions to see the package insert for use.*

FDA Label Image

Mm3 (Duloxetine 60mg 70518 1011 02)

Label for Duloxetine 60 mg delayed-release capsules, quantity of 60, repackaged by RemedyRepack Inc. The label includes designation as RX only, NDC number 70518-1011-02, manufacturer listed as Ajanta Pharma Ltd., India, and storage instructions. Barcode and QR code are visible on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.